The Organophosphate and Carbamate Poisoning drugs in development market research report provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Organophosphate and Carbamate Poisoning. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Organophosphate and Carbamate Poisoning by nine companies/universities/institutes. The top development phase for Organophosphate and Carbamate Poisoning is preclinical with seven drugs in that stage. The Organophosphate and Carbamate Poisoning pipeline has five drugs in development by companies and four by universities/ institutes. Some of the companies in the Organophosphate and Carbamate Poisoning pipeline products market are: Hebrew University of Jerusalem, Texas A&M University and Mississippi State University.
The key targets in the Organophosphate and Carbamate Poisoning pipeline products market include Acetylcholinesterase, and Gamma Aminobutyric Acid Type A Receptor Subunit.
The key mechanisms of action in the Organophosphate and Carbamate Poisoning pipeline product include Acetylcholinesterase Activator with two drugs in Preclinical. The Organophosphate and Carbamate Poisoning pipeline products include one routes of administration with the top ROA being Oral and three key molecule types in the Organophosphate and Carbamate Poisoning pipeline products market including Small Molecule, and Oligonucleotide.
Organophosphate and Carbamate Poisoning overview
Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.
For a complete picture of Organophosphate and Carbamate Poisoning’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
